REG - Hutchmed China Ltd - Overseas Regulatory Announcement

HUTCHMED (China)Announcement

28/01/2025 09:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250128:nRSb9427Ua&default-theme=true

RNS Number : 9427U  Hutchmed (China) Limited  28 January 2025

Overseas Regulatory Announcement -

Disposal Transaction

 

 

HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ") notes the
below text, which is from an announcement released to the Stock Exchange of
Hong Kong Limited on January 28, 2025 pursuant to Chapter 14 of the Rules
Governing the Listing of Securities on The Stock Exchange of Hong Kong
Limited. The text relates to the dispatch timing of the extraordinary general
meeting circular that relates to the transaction described in the announcement
dated January 2, 2025, entitled "HUTCHMED Announces US$608 million Divestment
of Non-Core Joint Venture".

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial‑stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Since inception it has
focused on bringing cancer drug candidates from in‑house discovery to
patients around the world, with its first three medicines marketed in China,
the first of which is also approved in the US, Europe and Japan. For more
information, please visit: www.hutch-med.com (http://www.hutch-med.com) or
follow us on LinkedIn (https://www.linkedin.com/company/hutchmed/) .

 

 

CONTACTS

 Investor Enquiries                                   +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 FTI Consulting -                                     +44 20 3727 1030 / HUTCHMED@fticonsulting.com
                                                      (mailto:HUTCHMED@fticonsulting.com)
 Ben Atwell / Alex Shaw                               +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
 Brunswick - Zhou Yi                                  +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                      (mailto:HUTCHMED@brunswickgroup.com)

 Panmure Liberum                                      Nominated Advisor and Joint Broker
 Atholl Tweedie / Freddy Crossley / Rupert Dearden    +44 20 7886 2500

 HSBC                                                 Joint Broker
 Simon Alexander / Alina Vaskina / Arnav Kapoor       +44 20 7991 8888

 Cavendish                                            Joint Broker
 Geoff Nash / Nigel Birks                             +44 20 7220 0500

 

 

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong
Limited take no responsibility for the contents of this announcement, make no
representation as to its accuracy or completeness and expressly disclaim any
liability whatsoever for any loss howsoever arising from or in reliance upon
the whole or any part of the contents of this announcement.

 

 

HUTCHMED (China) Limited
和黃醫藥（中國）有限公司
(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 13)

 

MAJOR TRANSACTION

IN RELATION TO

THE DISPOSAL OF 45% EQUITY INTEREST IN

SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED

 

TIMING OF DISPATCH OF CIRCULAR

 

Reference is made to the announcement of HUTCHMED (China) Limited (the
"Company") dated January 1, 2025 (the "Announcement") in relation to the
proposed disposal of 45% equity interest in Shanghai Hutchison Pharmaceuticals
Limited. Unless otherwise defined, capitalized terms used in this announcement
shall have the same meanings as those defined in the Announcement.

 

In the Announcement, it was mentioned that the Circular containing, among
other things, (i) further details on the terms of the Proposed Disposal; and
(ii) other information as required under the Listing Rules together with a
notice convening the EGM, was expected to be dispatched to the Shareholders on
or before January 28, 2025.

 

GP Health Service Capital has notified the Seller that additional time is
required for it to designate the GP Purchaser Fund and the Designated
Purchaser, taking into account the Chinese New Year holidays. In view of this,
the Company currently expects that the Circular will be dispatched to the
Shareholders on or before February 28, 2025.

 

The Proposed Disposal is subject to all of the conditions under the Agreements
being satisfied (or, if applicable, waived) and therefore may or may not
become unconditional. If any of the conditions under the Agreements is not
satisfied (or, if applicable, waived), the Proposed Disposal will not proceed.
Shareholders and potential investors are reminded to exercise caution when
dealing in the shares and other securities of the Company.

 

By Order of the Board

Edith Shih
Non-executive Director and Company Secretary

 

Hong Kong, January 28, 2025

 

As at the date of this announcement, the Directors of the Company are:

 Chairman and Non-executive Director:  Non-executive Directors:

 Dr Dan ELDAR                          Ms Edith SHIH

                                       Ms Ling YANG

 Executive Directors:

 Dr Weiguo SU                          Independent Non-executive Directors:

 (Chief Executive Officer and          Mr Paul Rutherford CARTER

Chief Scientific Officer)

                                     (Senior Independent Director)
 Mr CHENG Chig Fung, Johnny

                                     Dr Renu BHATIA
 (Chief Financial Officer)

                                       Dr Chaohong HU

                                       Mr Graeme Allan JACK

                                       Professor MOK Shu Kam, Tony

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBPMPTMTBTMRA